{
  "attach_pages": "56",
  "attach_size": "5067",
  "attach_type": "0",
  "attach_url": "https://pdf.dfcfw.com/pdf/H3_AP201906281336784206_1.pdf?1601214723000.pdf",
  "company_code": "80045894",
  "eitime": "2019-06-28 18:37:45",
  "extend": {},
  "info_code": "AP201906281336784206",
  "language": "0",
  "notice_date": "2019-06-28 00:00:00",
  "notice_title": "智飞生物深度报告：产品及研发管线存在显著预期差，疫苗绝对龙头长期市值有望突破2000亿",
  "page_size": 1,
  "page_size_ch": 0,
  "page_size_cht": 0,
  "page_size_en": 0,
  "rating": "CCC",
  "researcher": "崔文亮,蔡承霖",
  "security": [
    {
      "market_uni": "0",
      "publish_relation": [
        {
          "originalCode": "1044",
          "publishName": "生物制品"
        }
      ],
      "short_name": "智飞生物",
      "short_name_ch": "智飞生物",
      "short_name_cht": "智飛生物",
      "short_name_en": "ZHIFEI-BIOL",
      "stock": "300122"
    }
  ],
  "short_name": "智飞生物",
  "source_sample_name": "诚通证券",
  "star": "4"
}